Evidence map›Paper›PMID 29935386›Full record

ArticleBiomaterials2018

Correlating quantitative tumor accumulation and gene knockdown using SPECT/CT and bioluminescence imaging within an orthotopic ovarian cancer model.

Steven K Jones, Kirk Douglas, Anthony F Shields, Olivia M Merkel

Abstract read
In one paragraph

Article in Biomaterials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Engineering poly- and micelleplexes for nucleic acid delivery - A reflection on their endosomal escape.Journal of controlled release : official journal of the Controlled Release Society · 2023
    Review
  5. Review
  6. Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020
    Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Steven K JonesDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.
Kirk DouglasDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Anthony F ShieldsDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
Olivia M MerkelDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA; Department of Pharmaceutical Sciences, Wayne State University School of Pharmacy and Health Sciences, Detroit, MI, USA; Department of Pharmacy, Pharmaceutical Technology and Biopharmacy, Ludwig-Maximilians-Universität München, Munich, Germany. Electronic address: Olivia.merkel@LMU.de.
The Barbara Ann Karmanos Cancer Institute · USLudwig-Maximilians-Universität München · DEWayne State University · US

Funding

TRAINING PROGRAM IN THE BIOLOGY OF CANCERT32CA009531 · NCI · WAYNE STATE UNIVERSITY · PI Larry H Matherly · 1985 to 2026
$5.3M
NCI NIH HHS T32 CA009531
6 · The paper itself

Abstract

Using an orthotopic model of ovarian cancer, we studied the delivery of siRNA in nanoparticles of tri-block copolymers consisting of hyperbranched polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol) (hyPEI-g-PCL-b-PEG) with and without a folic acid targeting ligand. A SKOV-3/LUC FRα overexpressing cell line was employed to mimic the clinical manifestations of ovarian cancer. Both targeted and non-targeted micelleplexes were able to effectively deliver siRNA to the primary tumor and its metastases, as measured by gamma scintillation counting and confocal microscopy. Stability of the micelleplexes was demonstrated with a serum albumin binding study. Regarding biodistribution, intravenous (I.V.) administration showed a slight advantage of FRα targeted over non-targeted micelleplex accumulation within the tumor. However, both formulations displayed significant liver uptake. On the other hand, intraperitoneally (I.P.) injected mice showed a modest 6% of the injected dose per gram (ID/g) uptake within the primary and most interestingly also in the metastatic lesions which subsequently resulted in a 62% knockdown of firefly luciferase expression in the tumor after a single injection. While this is, to the best of our knowledge, the first paper that correlates quantitative tumor accumulation in an orthotopic tumor model with in vivo gene silencing, these data demonstrate that PEI-g-PCL-b-PEG-Fol conjugates are a promising option for gene knockdown in ovarian cancer.

Indexed as

Gene Knockdown TechniquesSingle Photon Emission Computed Tomography Computed TomographyAnimalsCell Line, TumorDisease Models, AnimalEndocytosisFemaleIndium RadioisotopesLuciferasesLuminescent MeasurementsMice, NudeOvarian NeoplasmsRNA, Small InterferingSubcellular FractionsTissue DistributionIndium-111Indium RadioisotopesLuciferasesRNA, Small InterferingFolate receptor alphaFolate receptor targetingOvarian cancerOvarian cancer xenograftPolymer micelleplexessiRNA delivery

Identifiers

PMID29935386
PMCPMC6056733
OpenAlexW2808701049

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.